From: Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities
Methylated gene(s) | Methylation association | Hazard ratioa | Reporting study |
---|---|---|---|
WIF1, TFPI2, RASSF1A and SOCS1 | Advanced clinical stage | – | [34] |
17-gene (see text) | Overall survival | 2.41 (1.02–5.7) | [120] |
RASSF1A, RAR-beta2, MGMT | Shorter overall survival | 2.38 (1.1–4.8) | [117] |
KIT, DSP, HCK, IL18 | Shorter overall survival | – | [45] |
HOXD9 | Shorter overall survival | 2.7 (1.1–6.5) | [49] |
LINE-1 | Shorter overall survival | 2.63 (1.2–5.6) | [110] |
MINT31 | Longer overall survival | 0.237 (not reported) | [34] |
TFPI2 | Presence of metastases | – | [172] |
PTEN | Shorter overall survival | 3.76 (1.2–11.1) | |
MGMT | Response to therapy | - | [113] |
Longer progression-free survival | 2.17 (1.3–3.5) | ||
TSLC1 | Progression-free survival | - | [112] |
RASSF1A | Resistance to therapy | 0.21 (0.1–0.9) | [117] |
ESR1 | Shorter overall survival | 2.31 (1.4–5.5) | [161] |
Shorter progression free survival | 2.64 (1.3–5.1) | ||
p73 | Sensitivity to therapy | – | [173] |